Portal de Periódicos da CAPES

Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

2016; BioMed Central; Volume: 16; Issue: 1 Linguagem: Inglês

10.1186/s12885-016-2766-3

1471-2407

André Hennigs, Fabian Riedel, Ádám Gondos, Hans‐Peter Sinn, Peter Schirmacher, Frederik Marmé, Dirk Jäger, Hans‐Ulrich Kauczor, Anne Stieber, Katja Lindel, Jürgen Debus, Michael Golatta, Florian Schütz, Christof Sohn, Jörg Heil, Andreas Schneeweiß,

Lung Cancer Treatments and Mutations

In Germany, most breast cancer patients are treated in specialized breast cancer units (BCU), which are certified, and routinely monitored. Herein, we evaluate up-to-date oncological outcome of breast cancer (BC) molecular subtypes in routine clinical care of a specialized BCU.The study was a prospectively single-center cohort study of 4102 female cases with primary, unilateral, non-metastatic breast cancer treated between 01 January 2003 and 31 December 2012. The five routinely used molecular subtypes (Luminal A-like, Luminal B/HER2 negative-like, Luminal B/HER2 positive-like, HER2-type, Triple negative) were analyzed. The median follow-up time of the whole cohort was 55 months. We calculated estimates for local control rate (LCR), disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and relative overall survival (ROS).Luminal A-like tumors were the most frequent (44.7 %) and showed the best outcome with LCR of 99.1 % (95 % CI 98.5; 99.7), OS of 95.1 % (95 % CI 93.7; 96.5), and ROS of 100.0 % (95 % CI 98.5; 101.5). Triple negative tumors (12.3 %) presented the poorest outcome with LCR of 89.6 % (95 % CI 85.8; 93.4), OS of 78.5 % (95 % CI 73.8; 83.3), and ROS of 80.1 % (95 % CI 73.8; 83.2).Patients with a favorable subtype can expect an OS above 95 % and an LCR of almost 100 % over 5 years. On the other hand the outcome of patients with HER2 and Triple negative subtypes remains poor, thus necessitating more intensified research and care.